Introduction

Imagine watching a family member slowly lose the ability to walk, speak, and even remember you because of a fault in the gene. This is the painful reality for families affected by Huntington’s disease, a rare inherited disorder that affects both body and mind. For decades, we could only manage symptoms, but advances in gene therapy are now reigniting hope for thousands of families worldwide.

What is Huntington’s disease and why gene therapy?

Huntington’s disease (HD) is a genetic disorder of the brain that gets worse over time. It occurs when there is a problem with the Huntingtin (HTT) gene, which makes the Huntingtin protein. This protein helps nerve cells work properly. When the gene is faulty, it creates extra CAG (cytosine, adenosine, and guanine) repeats in the huntingtin protein, making the protein abnormally long and toxic to neurons. Common symptoms include problems with movement (such as involuntary jerking or loss of coordination), a gradual decline in thinking and memory, and changes in mood or behavior.¹

Most neurological disorders are caused by mutations in multiple genes. Huntington's Disease has a single genetic target (HTT gene), making it an ideal model for gene therapy. Gene therapy offers a way to directly target and correct or silence the defective gene, rather than only treating the symptoms.² 

This article aims to summarize the main gene therapy approaches, delivery methods, trial status, risks, and ethical challenges involved.

How does gene therapy work

Huntington’s disease (HD) is caused by a mutation in the HTT gene that produces an abnormal huntingtin protein. Hence, potential gene therapies for Huntington’s disease include those targeting huntingtin DNA and RNA, clearance of huntingtin protein, and DNA repair pathways.

• One way to lower the mutant HTT gene expression is by using antisense oligonucleotides (ASOs), which are short DNA strands that help block the production of harmful proteins
• Mutant HTT gene expression can also be silenced using RNA interference, where small RNAs (RNAi) are used to turn off the HTT gene
• Another strategy is to correct or replace the faulty HTT gene using new gene-editing tools such as CRISPR/Cas9, which work like molecular scissors to edit DNA
• Changing how DNA repair works can also help to treat Huntington’s disease. This could mean blocking repair pathways that are too active or using ASOs or RNAi to silence related genes³

Major gene therapy strategies under study

Scientists working on Huntington’s disease are looking into gene therapy to lower or stop the production of the harmful mutant huntingtin protein. The main strategies that are being studied and showing promising results are listed below.

Antisense oligonucleotides (ASOs)

• ASOs are short, synthetic strands of DNA designed to bind to the messenger RNA (mRNA) that carries the instructions for making the huntingtin protein
• They can block the mRNA from being translated into the mutated Huntingtin protein or promote its degradation

Allele-selective ASOs

• Allele-selective ASOs (antisense oligonucleotides) aim to turn off only the mutant version of the HTT gene, while leaving the normal copy alone
• This is important because accidentally silencing the normal copy could disrupt essential brain functions that rely on the normal huntingtin protein

RNA interference (RNAi) based therapies

• These use small RNA molecules, such as siRNA (small interfering RNA) or miRNA (microRNA), to interfere with Huntingtin mRNA and stop the production of the harmful protein
• RNAi therapies can be delivered with viral vectors, so they may last longer than ASOs, which require repeated injections

Viral vector-based gene therapy (AAV Delivery)

• One promising approach uses adeno-associated viral vectors (AAVs) to deliver genetic material directly into brain cells
• The treatment involves one surgical injection into certain parts of the brain, intending to permanently lower mutated huntingtin protein levels² 

New hope for Huntington’s patients

Clinical research on these gene therapy strategies is progressing quickly and showing promising results. Recent advances in Antisense Oligonucleotides (ASOs), Allele-Selective ASOs, and Viral Vector-Based Gene Therapy (AAV Delivery) are bringing gene therapy closer to becoming a viable treatment for Huntington’s disease. 

• The best-known ASO, tominersen (RG6042), developed by Roche and Ionis Pharmaceuticals, has shown promise in early trials. However, the Phase III trial was paused due to mixed results and concerns about long-term safety and benefit. Ongoing research continues to refine ASO therapies to make them more specific, stable, and longer lasting
• WVE-120101 and WVE-120102, developed by Wave Life Sciences, target single-nucleotide polymorphisms (SNPs) found only in the mutant gene. Early trials showed modest reductions in mutant Huntingtin protein, but further optimization is underway to improve their effectiveness² 
• In a recent breakthrough, AMT-130 (developed by Uniqure) has shown promising results in a phase 1/2 clinical trial. This therapy aims to slow the progression of the disease by reducing the amount of mutated huntingtin protein in the brain. AMT-130 was mostly safe, and patients handled it well

These results give hope that gene therapy could one day be a long-term treatment for people with Huntington’s disease. Although these results are promising, further studies are needed to confirm that the therapy is effective and safe over time. Still, this is an important step toward finding new treatments for neurodegenerative diseases.⁴

Risks, challenges, and ethical considerations

Gene therapies for neurological diseases such as Huntington's disease offer hope for many patients, but they also raise various risks and ethical challenges.

• Timing of clinical trials: Despite advances in gene therapy, the strategies remain complex and novel. Hence, any first-in-human trial should be supported by very strong and reproducible preclinical findings, especially where vectors are expected to persist in tissues and where delivery is invasive
• Special access and compassionate use: When patients ask for non-authorised therapies outside of clinical trials, it can create conflicts with safety, use of resources, and scientific progress. Allowing early access might slow down research and put patients at risk
• Individualised therapy: Custom gene therapies are made to fix a patient’s specific genetic mutations and are sometimes paid for by the patients themselves. This raises ethical questions about consent, research oversight, and whether patient funding could affect scientific standards
• Patient selection: Deciding which patients to include in a clinical trial is always a challenge. One approach is called risk escalation, where researchers start with patients who have advanced disease before including those with early-stage illness. This helps reduce harm and improve our understanding of the disease
• Unintended effects: Gene therapy in the brain can lead to unexpected changes, like effects on deep brain stimulation, sex drive, body image, or personality. As gene therapy is used for more long-term conditions, these issues will need careful attention
• Comparators and Sham Interventions: Many gene therapy trials for neurological diseases require surgery to deliver the treatment. To make sure the results are valid, some studies use sham procedures, or fake surgeries, as controls. This raises ethical concerns because these procedures are invasive, do not help the patient, and involve some level of deception
• Consent: Children with congenital disorders cannot legally give consent, and patients with Alzheimer’s or advanced Parkinson’s disease may not be able to fully understand or make informed decisions about joining these trials
• Cost and access: Gene therapies are extremely expensive, raising issues of fairness, reimbursement, and global inequity⁵

FAQs

Is there a cure for Huntington’s disease?

There is no cure for Huntington’s disease yet. However, gene therapy is giving people hope because it aims to fix the error at the gene level.2. How does gene therapy work for Huntington’s disease?

Gene therapy works by lowering or turning off the faulty HTT (Huntingtin) gene. This stops harmful proteins from building up and damaging brain cells.³

What are the latest Huntington’s disease clinical trials?

AMT-130, which uses adeno-associated viral vectors (AAVs), has shown 75% slowing of disease progression and was safe in patients.⁴

Is gene therapy safe for Huntington’s disease?

Despite promising results, gene therapy for Huntington’s disease is still in early-stage clinical trials.  Because it involves complex brain procedures and long-lasting effects, its safety isn’t fully known. Hence, it is difficult to conclude about the safety of gene therapy.⁵

Who can participate in Huntington’s disease research trials?

Early trials usually include people with more advanced Huntington’s disease to test safety and delivery. Once these basics are understood, later trials may involve those in earlier stages to fine-tune dosing and treatment details.⁵

Summary

Huntington’s disease (HD) is a rare inherited brain disorder caused by a mutation in the HTT gene, which makes the huntingtin protein toxic to the nerve cells, affecting movement, memory, and mood. Gene therapy is now offering hope by addressing the disease at its genetic root.

Researchers are looking into several new treatments, including antisense oligonucleotides (ASOs), RNA interference (RNAi), and viral vector-based therapy (AAV). AMT-130 treatment, using adeno-associated viral vectors (AAV), has shown early signs of success, giving hope to families living with HD.

However, gene therapy also comes with risks, challenges, and ethical concerns. Clinical trials must balance safety, ethics, and ensuring patients, particularly children and those unable to make decisions for themselves, understand what is involved. There are also concerns about cost, fair access, and the ethics of using fake surgeries in studies.

Despite these challenges, gene therapy is a big step forward. With more research and a strong focus on ethics, it could eventually bring lasting relief and real hope to people with Huntington’s disease.